Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines

NCT00644059 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

4902

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza, Human

Interventions

BIOLOGICAL: Adjuvanted trivalent inactivated subunit influenza vaccine
BIOLOGICAL: Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine
BIOLOGICAL: Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine

Sponsor

Novartis

Collaborators

[object Object]